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INTRODUCTION 
Distal pancreatectomy (DP) is the operation of choice for
benign or malignant disease in the body or tail of the pancreas.
Splenectomy in conjunction with distal pancreatectomy is
clearly indicated in most patients with adenocarcinoma of
the pancreas, as splenic preservation may compromise the
oncologic resection. However, for benign lesions or tumors
with low-grade malignant potential, the issue of splenic preser-
vation remained controversial. To reduce the risk of post-
splenectomy sepsis and hematologic disorders, several authors
have emphasized the benefits of spleen preservation (1-3).
On the other hand, some authors suggest that splenic preser-
vation is more difficult, time-consuming, and is associated
with increased blood loss from small venous tributaries (4).
Thus, the aim of this study was to evaluate the clinical
efficacy of spleen-preserving distal pancreatectomy (SPDP)
by comparing the perioperative factors and postoperative
courses between DP and SPDP for benign lesions or tumors
with low-grade malignant potential of the body and tail of
the pancreas. 
MATERIALS AND METHODS
From January 1995 to April 2006, 143 patients underwent
DP and the 37 patients underwent SPDP for benign or low-
grade malignant disease at Seoul National University Hos-
pital, Seoul, South Korea. Spleen preservation was achieved
in which the pancreas was dissected off the splenic vessels.
The medical records were reviewed to evaluate the clinical
outcomes such as surgical factors (operation time, estimated
blood loss, transfusion), postoperative complications, and
postoperative long-term outcomes (endocrine/exocrine func-
tion, and recurrence).
Of these, laparoscopic DP was performed in 14 patients
and laparoscopic SPDP in one patient.
Vaccination against Pneumococcus, Haemophilus influenza b
and Neisseria meningitides was not performed routinely.
DP was performed in a standard fashion. Division of the
pancreatic parenchyma was conducted via electrocautery and
mass. Direct ligation of the main pancreatic duct was done
with non-absorbable suture. The pancreatic stump was over-
sewn with suture reinforcement using 4-0 black silk or 4-0
polypropylene (prolene*, Ethicon, Somerville, NJ, U.S.A.).
For the laparoscopic DP, the pancreas was transected using
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Clinical Comparison of Distal Pancreatectomy with or without
Splenectomy
The spleen may be preserved during distal pancreatectomy (DP) for benign dis-
ease. The aim of this study was to compare the perioperative and postoperative
courses of patients with conventional DP and spleen-preserving distal pancreatec-
tomy (SPDP) for benign lesions or tumors with low-grade malignant potential occurred
at the body or tail of the pancreas. A retrospective analysis was performed for the
hospital records of all the patients undergoing DP and SPDP between January 1995
and April 2006. One-hundred forty-three patients underwent DP and 37 patients
underwent SPDP. There were no significant differences in age, sex, indications of
operation, estimated blood loss, operative time, and postoperative hospital stay
between the two groups. Pancreatic fistula occurred in 21 (13.3%) patients follow-
ing DP and in 3 (8.1%) following SPDP without a significant difference (p=0.081).
Portal vein thrombosis occurred in 4 patients after DP. Splenic infarction occurred
in one patient after SPDP. Overwhelming postosplenectomy infection was observed
in one patient after DP. SPDP can be achieved with no increase in complication
rate, operative time, or length of postoperative hospitalization as compared to con-
ventional DP. Additionally, it has the advantage of reducing the risk of overwhelm-
ing postsplenectomy infection and postoperative venous thrombosis. 
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Accepted : 4 March 2008the 48- or 35-mm vascular endoscopic linear stapler (Endo-
GIA stapler with vascular cartridge; Autosuture Corp., Nor-
walk, CT, U.S.A.). In SPDP, both splenic artery and vein
were preserved. One closed suction drain was positioned in
the splenic fossa close to the transected pancreas. In SPDP,
both the splenic artery and vein were preserved. 
A pancreatic fistula was defined as drainage of more than
30 mL of fluid with an amylase level higher than 600 U/dL
on or after postoperative week 1 (5). Postoperative octreotide
was given subcutaneously (dose 100 mg every 8 hr) for the
patients considered high risk for pancreatic fistula based on
the gland texture and duct size.
Comparison of outcomes between the two groups was per-
formed using the chi-square test and Student’s t-test where
appropriate. Results are reported as mean±standard devia-
tion. Statistical significance was accepted at p<0.05.
RESULTS
Clinical features of patients and indications for DP with
or without splenectomy are shown in Table 1. There were no
significant differences in age, sex, preoperative diabetes mel-
litus, preoperative WBC count, platelet count, and indica-
tions.
SPDP was successfully performed in all 37 patients. Con-
servation of the splenic artery and vein during SPDP was
possible in all patients. 
Four patients in the DP group and one patient in the SPDP
group underwent pancreaticojejunostomy due to the stric-
ture of proximal pancreatic duct caused by chronic pancre-
atitis. 
There were no postoperative deaths. Operative details and
postoperative complications are shown in Table 2. There were
no significant differences in estimated blood loss, intraoper-
ative transfusion and operative time between the two groups.
The white blood cells (WBC) and the platelet counts exam-
ined one week after operation were significantly higher in
the DP group than the SPDP group (p<0.05). The incidence
of complications was 27.3% (39/143) in the DP group com-
paring 21.6% (8/37) in the SPDP group, and this was not
statistically significant. The incidence of pancreatic fistula
in the DP group was 14.7% (21/143) and 8.1% (3/37) in
the SPDP group. There was no significant difference between
the two groups. For 85 patients in the DP group and 18
patients in the SPDP group, prophylactic octreotide was
1012 S.E. Lee, J.-Y. Jang, K.U. Lee, et al.
Characteristic
DP group
(n=143)
SPDP group
(n=37)
p
value
Age (yr) 52±15 48±14 0.51
Gender (female:male) 1.7:1 2.1:1 0.85
Preoperative diabetes mellitus 16 (11%) 4 (11%) 0.61
White blood cell count (/μ L) 7,140±9,987 5,486±1,552 0.33
Platelets count (10
3/μ L) 231±78 235±57 0.81
Indication 0.47
Cystic neoplasm 47 (33%) 12 (33%)
Serous cystic neoplasm 15 7
Mucinous cystic neoplasm 32 5
IPMN 31 (22%) 11 (30%)
Neuroendocrine tumor 16 (11%) 3 (8%)
Solid pseudopapillary neoplasm 16 (11%) 7 (19%)
Others* 34 (24%) 4 (11%)
Table 1. Preoperative findings in patients undergoing distal pan-
createctomy with splenectomy (DP group) and without splenec-
tomy (SPDP group)
*, Others include pseudocyst, chronic pancreatitis, benign cyst, cystic
lymphangioma, lymphoepithelial cyst, SMA aneurysm, arteriovenous
malformation, pleuropancreatic fistula, accessory spleen, splenic artery
rupture, splenic hematoma.
DP, distal pancreatectomy; SPDP, spleen-preserving distal pancreate-
ctomy; IPMN, intraductal papillary mucinous neoplasm.
DP group
(n=143)
SPDP group
(n=37)
p
value
Estimated blood loss (mL) 544±1,139 396±368 0.46
Intraoperative transfusion (yes) 12 (8.4%) 2 (5.4%) 1.00
Operative time (min) 211±94 215±86 0.84
Use of prophylactic octreotide  85 (59.4%) 18 (48.6%) 1.00
White blood cell count (/μ L) at  9,408±4,824 7,074±3,076 0.008
POD7
Platelets count (10
3/μ L) at POD7 468±167 299±80 <0.001
Complications 39 (27.3%) 8 (21.6%) 1.00
Pancreatic fistula 21 (14.7%) 3 (8.1%) 0.13
Fluid collection 11 (7.7%) 2 (5.4%) 0.43
Portal/splenic vein thrombosis 4 (2.8%) 0 0.172
Splenic infarction 0 1 (2.7%) 0.074
Others* 6 (4.2%) 2 (5.4%) 1.00
Hospital stay (days) 15±91 6 ±9 0.41
Table 2. Perioperative details and complications  
Data are given as mean±standard deviation.
*, Others include wound problem, tractitis, chyloperitoneum. 
DP, distal pancreatectomy; SPDP, spleen-preserving distal pancreate-
ctomy.
DP, distal pancreatectomy; SPDP, spleen-preserving distal pancreate-
ctomy. 
DP group
(n=143)
SPDP group
(n=37)
p
value
Follow-up (months) 36±33 41±30 0.43
White blood cell count (/μ L) at  7,811±2,727 5,811±1,656 <0.001
6 months after operation
Platelets count (10
3/μ L) at   390±168 296±159 0.002
6 months after operation
Diabetes mellitus
Newly developed 16 (11%) 4 (11%) 1.00
Unchanged 16  (11%) 4  (11%) 1.00
Aggravated 0 0
Recurrence of disease 1 (0.69%) 0 1.00
Table 3. Long-term outcome  used. Of these patients, pancreatic fistula occurred in 10
patients (11.8%, 10/85) of the DP group and in one patient
(5.6%, 1/18) of the SPDP group. The mean duration of hos-
pital stay was 15±9 days for patients in the DP group and
16±9 days for the SPDP group. Splenic vein thrombosis
occurred in one patient who underwent DP. He received
anticoagulation treatment and there was no more progres-
sion of the thrombosis. Portal vein thrombosis occurred in
three patients after DP. They received no specific treatment,
and spontaneous resolution of the thrombosis occurred as
detected by radiologic imaging studies. Splenic infarction
occurred in one patient of the SPDP group. On the CT scan
4 yr after surgery, the appearance of volume loss with multi-
focal low attenuated lesions of the spleen with an intact splenic
artery was detected without any overt symptoms. The patient
is still alive with no issues 7 yr after surgery. There was one
patient who was suspected of overwhelming postsplenecto-
my sepsis (OPSI) and this was the only patient who experi-
enced septic shock in our study. A 65-yr-old male patient
who was previously healthy underwent DP with splenecto-
my due to intraductal papillary mucinous neoplasm. On the
9th postoperative day, fever developed and on ultrasonogra-
phy, small fluid collection was ob- served near the DP site.
Percutaneous drainage was performed and 30 mL of pus-like
fluid was aspirated. Next day, he became suddenly hypoten-
sive but no additional finding was detected on abdominal
CT comparing ultrasonographic images received the previ-
ous day. Shewanella algae was cultured from peripheral blood.
Intravenous antibiotics treatment was performed and his
medical condition had been improved.
The mean follow-up period was 36±33 months in the DP
group and 41±30 months in the SPDP group (Table 3).
The WBC and the platelet counts examined at 6 months
after the operation were significantly higher in the DP group
than the SPDP group (p<0.05). Regarding endocrine func-
tion, 16 and 4 patients had diabetes mellitus in the DP group
and SPDP group, respectively. Diabetes did not get worse
in any patient following DP or SPDP. Among the patients
with preoperative normoglycemia, newly developed diabetes
mellitus was noted in 16 patients in the DP group and 4
patients in the SPPD group. There was no significant differ-
ence between the two groups. Recurrence occurred in one
patient 5 yr later after undergoing DP due to intraductal
papillary mucinous neoplasm. Total pancreatectomy was
performed and the permanent pathologic report showed intra-
ductal papillary mucinous carcinoma. 
DISCUSSION
Splenectomy during a DP is performed frequently because
of its technical simplicity and clear indication in the majori-
ty of patients with adenocarcinoma of the pancreas, as splenic
preservation may compromise the oncologic resection. How-
ever, SPDP has been performed because of increasing inter-
est in splenic salvage because of the increased risk of infec-
tion, changes in peripheral blood counts (6-8) and consider-
ation of overwhelming postsplenectomy sepsis (6-8).
There are currently four retrospective reviews comparing
outcomes after DP with or without splenectomy (4, 9-11).
Richardson and Scott-Conner (9) reported on 21 patients,
who underwent surgery for trauma, and found no differences
in complication rates between groups, concluding that sp-
lenectomy could be accomplished in selected cases. Aldridge
and Williamson (10) reported on 77 patients, who under-
went surgery for chronic pancreatitis, and also concluded that
the spleen can be preserved safely. Benoist et al. (11) found
in 40 patients with benign lesions other than pancreatitis
that the complication rate was twice as high in the splenic
preservation group as compared to the splenectomy patients.
They concluded that DP with splenectomy is the best pro-
cedure for benign disease of the tail and body of the pancreas.
In the largest series in the literature, Shoup et al. (4) evalu-
ated 125 patients who underwent DP for benign or low-
malignant potential tumors. In this series from Memorial
Sloan-Kettering Cancer Center, 79 patients underwent sple-
nectomy and 46 underwent splenic preservation. The over-
all complication rates were similar between the two groups;
however, patients undergoing splenectomy had a significantly
higher rate of infectious complications (28% for splenecto-
my, 9% for splenic preservation, p=0.01) and severe compli-
cations (11% vs. 2%, p=0.05) compared with those who
had splenic preservation. Their conclusion was that splenic
preserving DP is safe and can be performed with decreased
perioperative morbidity compared with conventional pan-
createctomy with splenectomy and should be the operation
of choice, when feasible, for distal pancreatic disease other
than adenocarcinoma.
In our study, splenic preservation has not increased the
operative time, intraoperative bleeding, complication rate
including pancreatic fistula, or length of hospital stay asso-
ciated with DP. However, there was only one patient who
was suspected of overwhelming postsplenectomy sepsis
(OPSI). OPSI had been defined as septicemia and/or menin-
gitis, usually fulminant but not necessarily fatal, occurring
at any time after removal of the spleen (12). Although the
incidence of infection after splenectomy in adults ranging
from 0.28% to 1.9% with a 2.2% mortality rate (13, 14)
may be low, the infections are fatal. Therefore, distal pancre-
atectomy with splenectomy should be the operation of choice,
when feasible.
In the present study, there were 3 patients who experienced
portal vein or splenic vein thrombosis after DP with splenec-
tomy due to non-hematologic disease. Their platelet counts
were less than 300×103/μ L at the time of diagnosis of venous
thrombosis. Fortunately, in all three patients, the extent of
venous thrombosis was reduced without specific treatment.
The presentation of portal vein thrombosis is vague, without
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index of suspicion, this complication may go undetected.
The progression of the thrombus to occlude the portal and
mesenteric veins could cause acute hypertension in the spla-
nchnic circulation resulting in intestinal infarction. Although
the reported incidence of this complication is low (15, 16),
even vague symptoms must be considered seriously follow-
ing splenectomy.
Our results show that SPDP with the preservation of the
splenic vessels can be safely performed without increasing
operative time, and length of postoperative hospitalization,
or increasing the postoperative complication rate. Addition-
ally, SPDP has the advantage of reducing the risk of over-
whelming postsplenectomy infection and postoperative
venous thrombosis. Therefore, SPDP is worth considering
for the treatment of benign or low-grade malignant poten-
tial lesions of the body or tail of the pancreas.
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